

Jennifer R Brown

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8158051/jennifer-r-brown-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

290
papers

15,371
citations

56
h-index

121
g-index

307
ext. papers

18,241
ext. citations

6.4
avg, IF

6.35
L-index

#	Paper	IF	Citations
290	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 311-22	59.2	1164
289	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 213-23	59.2	1154
288	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. <i>Cell</i> , 2013 , 152, 714-26	56.2	1006
287	SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2011 , 365, 2497-506	59.2	875
286	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <i>Journal of Clinical Oncology</i> , 2012 , 30, 488-96	2.2	622
285	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 323-32	59.2	621
284	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. <i>Nature</i> , 2014 , 511, 616-20	50.4	507
283	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 β for relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 123, 3390-7	2.2	487
282	Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. <i>Journal of Clinical Investigation</i> , 2007 , 117, 112-21	15.9	468
281	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018 , 379, 2517-2528	59.2	455
280	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , 2013 , 121, 2051-8	2.2	298
279	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1923-30	2.2	254
278	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , 2016 , 17, 1409-1418	21.7	233
277	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016 , 128, 195-203	2.2	222
276	Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2779-86	1.9	221
275	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016 , 7, 11589	17.4	220
274	Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. <i>Cancer Cell</i> , 2014 , 26, 813-825	24.3	216

273	A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>Blood</i> , 2014 , 123, 3398-405	2.2	206
272	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016 , 127, 3215-24	2.2	181
271	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2017 , 18, 297-311	21.7	173
270	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- β as therapy for previously treated indolent non-Hodgkin lymphoma. <i>Blood</i> , 2014 , 123, 3406-13	2.2	173
269	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 1353-1363	7.1	152
268	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017 , 102, 1796-1805	6.6	150
267	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology, the</i> , 2017 , 4, e114-e126	14.6	149
266	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020 , 136, 1134-1143	2.2	132
265	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019 , 133, 2031-2042	20.4	123
264	Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i> , 2017 , 129, 2581-2584	2.2	120
263	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2016 , 30, 750-763	24.3	115
262	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019 , 36, 369-384.e13	24.3	107
261	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 120, 3501-9	2.2	107
260	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 24-31	2.2	105
259	Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2011 , 17, 2977-86	12.9	103
258	Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2208-14	2.2	102
257	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019 , 3, 1553-1562	7.8	101
256	Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1056-64	4.7	99

255	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 125, 2915-22	2.2	92
254	The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF- κ B activation and induces apoptosis in chronic lymphocytic leukemia B cells. <i>Clinical Cancer Research</i> , 2014 , 20, 1576-89	12.9	91
253	Phosphatidylinositol 3-kinase β blockade increases genomic instability in B cells. <i>Nature</i> , 2017 , 542, 489-493	3.4	88
252	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016 , 172, 735-44	4.5	88
251	Cardiovascular Toxicities Associated With Ibrutinib. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1667-1678	15.1	85
250	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020 , 135, 1204-1213	2.2	81
249	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , 2021 , 397, 892-901	4.0	81
248	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 2931-2940	2.2	75
247	How I treat CLL patients with ibrutinib. <i>Blood</i> , 2018 , 131, 379-386	2.2	74
246	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2117-2125	4.7	70
245	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. <i>Lancet Haematology, the</i> , 2019 , 6, e38-e47	14.6	70
244	Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2012 , 18, 3791-802	12.9	69
243	A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. <i>British Journal of Haematology</i> , 2009 , 145, 741-8	4.5	69
242	Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. <i>Current Hematologic Malignancy Reports</i> , 2013 , 8, 1-6	4.4	68
241	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2362-70	1.9	68
240	Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. <i>Blood</i> , 2015 , 125, 2779-85	2.2	63
239	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. <i>Clinical Cancer Research</i> , 2017 , 23, 735-745	12.9	62
238	Clinical mimics of lymphoma. <i>Oncologist</i> , 2004 , 9, 406-16	5.7	58

237	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. <i>Blood</i> , 2016 , 128, 1609-13	2.2	58
236	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2018 , 34, 982-995.e7	24.3	58
235	Somatic mutation as a mechanism of Wnt/ β -catenin pathway activation in CLL. <i>Blood</i> , 2014 , 124, 1089-98	2.2	56
234	Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013 , 163, 123-6	4.5	56
233	Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2067-73	2.2	55
232	Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. <i>JAMA Dermatology</i> , 2014 , 150, 280-7	5.1	55
231	Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016 , 101, e295-8	6.6	54
230	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 574-83	2.2	54
229	Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1057-65	4.7	52
228	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. <i>Blood</i> , 2016 , 128, 2899-2908	2.2	52
227	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019 , 184, 558-569	4.5	51
226	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 42-8	2.2	50
225	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. <i>Genome Research</i> , 2017 , 27, 1300-1311	9.7	50
224	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019 , 570, 474-479	50.4	47
223	Phase I Trial of the Pan-PI3K Inhibitor Piliaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015 , 21, 3160-9	13.9	46
222	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 β In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2010 , 116, 1777-1777	2.2	45
221	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 741-769	64.1	45
220	PI3K β -selective and PI3K δ -combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1267-1279	5.9	44

219	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016 , 173, 89-95	4.5	44
218	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology, the</i> , 2019 , 6, e419-e428	14.6	41
217	Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2019 , 134, 762-762	2.2	41
216	Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?. <i>Expert Review of Hematology</i> , 2018 , 11, 185-194	2.8	38
215	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019 , 62, 1140-1147	5.2	38
214	CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 α Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 55-55	2.2	38
213	The treatment of relapsed refractory chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2011 , 2011, 110-8	3.1	33
212	The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016 , 43, 260-4	5.5	32
211	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020 , 4, 3977-3989	7.8	30
210	Voxtalisisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology, the</i> , 2018 , 5, e170-e180	14.6	28
209	Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. <i>Drugs and Aging</i> , 2017 , 34, 509-527	4.7	27
208	PI3K p110 α inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. <i>Journal of Clinical Investigation</i> , 2019 , 129, 122-136	15.9	27
207	Lenalidomide in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 633-650	5.9	25
206	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 32-32	2.2	25
205	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 1630-1630	2.2	25
204	Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. <i>PLoS ONE</i> , 2015 , 10, e0143685	3.7	25
203	Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. <i>Advanced Biology</i> , 2018 , 2, 1700167	3.5	23
202	Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 920-8	1.9	23

201	Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2008 , 143, 361-8	4.5	23
200	Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. <i>Leukemia and Lymphoma</i> , 2014 , 55, 263-9	1.9	22
199	A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. <i>British Journal of Haematology</i> , 2014 , 167, 149-61	4.5	22
198	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016 , 128, 3705-3705	2.2	22
197	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 858-867	7.8	21
196	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. <i>Blood</i> , 2020 , 136, 2918-2926	2.2	21
195	Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1823-5	1.9	21
194	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. <i>Blood</i> , 2015 , 126, 497-497	2.2	20
193	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019 , 94, 554-562	7.1	20
192	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE™ Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014 , 124, 3331-3331	2.2	19
191	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. <i>Nature</i> , 2021 , 590, 157-162	50.4	18
190	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 1391-1402	21.7	18
189	Novel treatments for chronic lymphocytic leukemia and moving forward. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e317-25	7.1	17
188	Inherited predisposition to chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2008 , 1, 51-61	2.8	17
187	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e387-98	7.1	17
186	Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. <i>Blood Advances</i> , 2020 , 4, 1458-1463	7.8	16
185	Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018 , 9, 3-19	5.7	16
184	Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015 , 170, 694-703	4.5	16

183	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016 , 128, 621-621	2.2	16
182	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , 2016 , 127, 2598-606	2.2	16
181	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019 , 3, 1167-1174	7.8	16
180	Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2004 , 45, 315-20	1.9	15
179	Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL. <i>Blood</i> , 2015 , 126, 490-490	2.2	15
178	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , 2020 , 4, e432	0.3	15
177	Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1390-8	4.7	14
176	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016 , 128, 3243-3243	2.2	14
175	Simultaneous inhibition of Vps34 kinase would enhance PI3K inhibitor cytotoxicity in the B-cell malignancies. <i>Oncotarget</i> , 2016 , 7, 53515-53525	3.3	14
174	Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. <i>Current Oncology Reports</i> , 2017 , 19, 61	6.3	13
173	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 20-21	2.2	13
172	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 4113-4123	7.8	13
171	Discovery of a Series of 5,11-Dihydro-6-benzo[<i>b</i>]pyrimido[5,4- <i>d</i>][1,4]diazepin-6-ones as Selective PI3K- γ Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016 , 7, 908-912	4.3	13
170	Chronic lymphocytic leukemia: a niche for flavopiridol?. <i>Clinical Cancer Research</i> , 2005 , 11, 3971-3	12.9	12
169	miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. <i>Blood</i> , 2021 , 137, 2481-2494	2.2	12
168	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021 , 35, 1064-1072	10.7	12
167	Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. <i>British Journal of Haematology</i> , 2010 , 151, 336-45	4.5	11
166	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020 , 136, 35-37	2.2	11

165	Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7505-7505	2.2	11
164	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7510-7510	2.2	11
163	Targeting Bruton's Tyrosine Kinase in CLL. <i>Frontiers in Immunology</i> , 2021 , 12, 687458	8.4	11
162	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 978-83	7.1	11
161	Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. <i>Blood Advances</i> , 2021 , 5, 3062-3065	7.8	11
160	Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2989-2992	2.2	10
159	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2013 , 98, 964-70	6.6	10
158	Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2437-8	2.2	10
157	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016 , 128, 641-641	2.2	10
156	Phosphatidylinositol 3 Kinase Inhibitors: Present and Future. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 394-400	2.2	10
155	Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021 , 96, E95-E98	7.1	10
154	Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. <i>Therapeutic Advances in Hematology</i> , 2013 , 4, 298-308	5.7	9
153	Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL. <i>Blood</i> , 2015 , 126, 4158-4158	2.2	9
152	A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL).. <i>Blood</i> , 2007 , 110, 3126-3126	2.2	8
151	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013 , 122, 86-86	2.2	8
150	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7520-7520	2.2	8
149	Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome. <i>Blood</i> , 2021 ,	2.2	8
148	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. <i>Lancet Haematology,the</i> , 2021 , 8, e912-e921	14.6	8

147	The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2287-2297	1.9	7
146	Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 329-39	3.1	7
145	Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?. <i>Expert Review of Hematology</i> , 2017 , 10, 707-718	2.8	7
144	Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 587-587	2.2	7
143	A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation. <i>Blood</i> , 2019 , 134, 4318-4318	2.2	7
142	Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18030-e18030	2.2	7
141	Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. <i>American Journal of Clinical Pathology</i> , 2004 , 121, 701-8	1.9	7
140	Characterization of selective and potent PI3K inhibitor (PI3KDIN- 015) for B-Cell malignances. <i>Oncotarget</i> , 2016 , 7, 32641-51	3.3	7
139	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	7
138	Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 138, 44-56	2.2	7
137	Relapsed CLL: sequencing, combinations, and novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 248-255	3.1	7
136	MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. <i>British Journal of Haematology</i> , 2019 , 184, 925-936	4.5	7
135	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021 , 106, 3219-3222	6.6	7
134	Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. <i>MAbs</i> , 2016 , 8, 787-98	6.6	6
133	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019 , 25, 5143-5155	12.9	6
132	B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. <i>ImmunoTargets and Therapy</i> , 2014 , 3, 29-38	9	6
131	LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL. <i>Blood</i> , 2019 , 134, 478-478	2.2	6
130	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019 , 134, 1763-1763	2.2	6

129	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. <i>Blood</i> , 2020 , 136, 46-47	2.2	6
128	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021 , 35, 3059-3072	10.7	6
127	Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. <i>Blood</i> , 2019 , 133, 990-992	2.2	6
126	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021 , 2, 54-69	7	6
125	Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1382-5	1.9	5
124	Insulin receptor activation in deletion 11q chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2011 , 17, 2605-7	12.9	5
123	NF- κ B Pathway Mutations Modulate Cell Survival and Ibrutinib Response In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 670-670	2.2	5
122	A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8004-8004	2.2	5
121	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. <i>PLoS ONE</i> , 2018 , 13, e0193249	3.7	5
120	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021 ,	24.4	5
119	Opportunistic Infections (OIs) in Patients with Hematologic Malignancies (HM) Treated with Bruton's Tyrosine Kinase (BTK) and Phosphoinositide 3 Kinase (PI3K) Inhibitors: An 8-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S699-S699	1	4
118	Physical Examination for the Academic Psychiatrist: Primer and Common Clinical Scenarios. <i>Academic Psychiatry</i> , 2016 , 40, 321-7	1.1	4
117	A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. <i>British Journal of Haematology</i> , 2017 , 178, 820-823	4.5	4
116	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018 , 132, 145-145	2.2	4
115	Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008 , 112, 972-972	2.2	4
114	Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution. <i>Blood</i> , 2013 , 122, 596-596	2.2	4
113	Altered Expression of Functional Proteins in CD4 Regulatory T Cells during Therapy with Idelalisib. <i>Blood</i> , 2015 , 126, 1735-1735	2.2	4
112	Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. <i>Blood</i> , 2016 , 128, 231-231	2.2	4

111	Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7581-TPS7581	2.2	4
110	Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target. <i>Frontiers in Immunology</i> , 2021 , 12, 662866	8.4	4
109	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021 , 35, 3201-3211	10.7	4
108	Idelalisib immune-related toxicity is associated with improved treatment response. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2915-2920	1.9	4
107	Ibrutinib: coming of age?. <i>Blood</i> , 2018 , 131, 1880-1882	2.2	3
106	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020 , 136, 47-48	2.2	3
105	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. <i>Blood</i> , 2011 , 118, 288-288	2.2	3
104	Functional Somatic and Germline Variants in the NF- κ B Pathway in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 560-560	2.2	3
103	Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 436-436	2.2	3
102	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 522-522	2.2	3
101	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021 , 11, 640731	5.3	3
100	The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. <i>Oncologist</i> , 2018 , 23, 288-296	5.7	3
99	DUO delivers for duvelisib. <i>Blood</i> , 2018 , 132, 2422-2424	2.2	3
98	Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S283	2	2
97	A new era of treatment for chronic lymphocytic leukaemia?. <i>Lancet Oncology, The</i> , 2014 , 15, 3-5	21.7	2
96	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020 , 136, 45-49	2.2	2
95	The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. <i>Blood</i> , 2020 , 136, 3-4	2.2	2
94	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018 , 132, 1856-1856	2.2	2

93	ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 5244-5244	2.2	2
92	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , 2007 , 110, 1358-1358	2.2	2
91	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4496-4496	2.2	2
90	Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro. <i>Blood</i> , 2013 , 122, 4132-4132	2.2	2
89	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 3156-3156	2.2	2
88	Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells. <i>Blood</i> , 2016 , 128, 4346-4346	2.2	2
87	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021 , 138, 639-639	2.2	2
86	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021 , 138, 391-391	2.2	2
85	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. <i>Blood</i> , 2019 , 134, 3321-3321	2.2	2
84	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. <i>Leukemia</i> , 2020 , 34, 3404-3407	10.7	2
83	IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K inhibitor idelalisib. <i>Haematologica</i> , 2021 , 106, 2995-2999	6.6	2
82	Ibrutinib: searching for a partner drug. <i>Lancet Oncology, The</i> , 2019 , 20, 3-5	21.7	2
81	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2021 , 39, 1099-1105	4.3	2
80	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021 , 35, 2854-2861	10.7	2
79	Inverting the BTK-BCL2 order. <i>Blood</i> , 2020 , 135, 2205-2207	2.2	1
78	Reply to S. Opat et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4094-4095	2.2	1
77	Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2767-2768	1.9	1
76	For CLL cells, there's no place like home. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3347-3349	1.9	1

75	Genomic approaches to chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 157-71	3.1	1
74	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. <i>Blood</i> , 2018 , 132, 4413-4413	2.2	1
73	Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial. <i>Blood</i> , 2019 , 134, 4312-4312	2.2	1
72	Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL. <i>Blood</i> , 2019 , 134, 1745-1745	2.2	1
71	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019 , 134, 4291-4291	2.2	1
70	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019 , 134, 1756-1756	2.2	1
69	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019 , 134, 3039-3039	2.2	1
68	A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.. <i>Blood</i> , 2010 , 116, 1381-1381	2.2	1
67	Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy. <i>Blood</i> , 2010 , 116, 59-59	2.2	1
66	Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , 2011 , 118, 2865-2865	2.2	1
65	Sensitivity to Wnt Pathway Inhibition in CLL Is Associated with Specific Gene Expression Signatures. <i>Blood</i> , 2011 , 118, 801-801	2.2	1
64	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012 , 120, 2875-2875	2.2	1
63	SF3B1 Mutation Alters The Selection Of 3' RNA Splice Sites In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 117-117	2.2	1
62	The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. <i>Blood</i> , 2015 , 126, 1486-1486	2.2	1
61	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 1713-1713	2.2	1
60	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. <i>Blood</i> , 2015 , 126, 4159-4159	2.2	1
59	Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia. <i>Cancer Research</i> , 2021 ,	10.1	1
58	Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies. <i>Molecular Oncology</i> , 2021 ,	7.9	1

57	BH3 Profiling Demonstrates That Restoration of Apoptotic Priming Contributes to Increased Sensitivity to PI3K Inhibition in Stroma-Exposed Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011 , 118, 974-974	2.2	1
56	High-grade heart block associated with ibrutinib therapy. <i>HeartRhythm Case Reports</i> , 2021 , 7, 391-394	1	1
55	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1312-1315	1.9	1
54	Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1986-1989	1.9	1
53	The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 807-826	3.1	1
52	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 22-23	2.2	0
51	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020 , 136, 37-38	2.2	0
50	Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL. <i>Blood</i> , 2011 , 118, 284-284	2.2	0
49	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021 , 138, 640-640	2.2	0
48	Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.. <i>Blood</i> , 2005 , 106, 2125-2125 ^{2.2}	2.2	0
47	Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 648925	5.7	0
46	AKT: a key to RT?. <i>Blood</i> , 2021 , 137, 582-584	2.2	0
45	The future of antibody therapy in chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 323-336	3.7	0
44	Obinutuzumab: its use in the management of chronic lymphocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 843-853	1.1	
43	The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2755-6	1.9	
42	4321 Personalization of T cell production for cellular immunotherapy. <i>Journal of Clinical and Translational Science</i> , 2020 , 4, 15-15	0.4	
41	Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e51	1.2	
40	Gastric mucosa-associated lymphoid tissue lymphoma resistant to Helicobacter pylori eradication: what's the best option?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 899-900	1.9	

- 39 Reply to J. Mehta. *Journal of Clinical Oncology*, **2009**, 27, e139-e140 2.2
- 38 Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement. *Blood*, **2020**, 136, 29-30 2.2
- 37 Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool. *Blood*, **2020**, 136, 41-42 2.2
- 36 Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing. *Blood*, **2021**, 138, 4361-4361 2.2
- 35 The Molecular Basis for BCL-2 Oncogene Addiction in CLL. *Blood*, **2005**, 106, 5008-5008 2.2
- 34 Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study. *Blood*, **2006**, 108, 4989-4989 2.2
- 33 Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse. *Blood*, **2006**, 108, 3041-3041 2.2
- 32 Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma. *Blood*, **2007**, 110, 2331-2331 2.2
- 31 Non-Myeloablative Allogeneic Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism. *Blood*, **2007**, 110, 3041-3041 2.2
- 30 Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI+FCR). *Blood*, **2018**, 132, 4395-4395 2.2
- 29 Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). *Blood*, **2018**, 132, 820-820 2.2
- 28 Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL. *Blood*, **2018**, 132, 5564-5564 2.2
- 27 High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2019**, 134, 2571-2571 2.2
- 26 Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). *Blood*, **2019**, 134, 516-516 2.2
- 25 Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. *Blood*, **2019**, 134, 3048-3048 2.2
- 24 Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202. *Journal of Clinical Oncology*, **2020**, 38, e20004-e20004 2.2
- 23 The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. *Blood*, **2015**, 126, 831-831 2.2
- 22 Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis. *Blood*, **2015**, 126, 4340-4340 2.2

21	Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination. <i>Blood</i> , 2015 , 126, 4124-4124	2.2
20	High Resolution Genomic Analysis In CLL Demonstrates Genomic Stability In Untreated Patients and Novel Markers of Progression In Treated Patients. <i>Blood</i> , 2010 , 116, 2426-2426	2.2
19	BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma. <i>Blood</i> , 2010 , 116, 692-692	2.2
18	Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk. <i>Blood</i> , 2010 , 116, 2457-2457	2.2
17	Amplification of 6p Associated with Familial CLL. <i>Blood</i> , 2010 , 116, 2432-2432	2.2
16	Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo. <i>Blood</i> , 2010 , 116, 2441-2441	2.2
15	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011 , 118, 465-465	2.2
14	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. <i>Blood</i> , 2011 , 118, 463-463	2.2
13	Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,. <i>Blood</i> , 2011 , 118, 3716-3716	2.2
12	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 1438-1438	2.2
11	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. <i>Blood</i> , 2011 , 118, 3669-3669	2.2
10	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 2728-2728	2.2
9	Somatic Mutation As a Mechanism of Wnt/ β Catenin Pathway Activation in CLL. <i>Blood</i> , 2012 , 120, 559-559	2.2
8	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012 , 120, 1892-1892	2.2
7	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. <i>Blood</i> , 2012 , 120, 3865-3865	2.2
6	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 3920-3920	2.2
5	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. <i>Blood</i> , 2012 , 120, 1980-1980	2.2
4	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 4567-4567	2.2

- 3 The Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. *Blood*, **2012**, 120, 5-5 2.2
- 2 Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL. *Blood*, **2013**, 122, 5300-5300 2.2
- 1 A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. *Leukemia and Lymphoma*, **2021**, 62, 478-481 1.9